Aptevo Therapeutics Q2 EPS $(1.67) Beats $(3.92) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics (NASDAQ:APVO) reported a Q2 EPS of $(1.67), significantly beating the analyst consensus estimate of $(3.92) by 57.4%. This represents a 96.9% improvement over the losses of $(53.95) per share from the same period last year.
August 08, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptevo Therapeutics reported a Q2 EPS of $(1.67), beating the analyst estimate of $(3.92) by 57.4%. This marks a significant improvement from the same period last year, where the company reported losses of $(53.95) per share.
The significant beat on EPS estimates and the substantial year-over-year improvement in losses are likely to positively impact APVO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100